Rosetta Therapeutics

Rosetta Therapeutics was a private Canadian biotech focused on discovering disease-modifying small molecule therapies for neurodegenerative diseases. The company combined proprietary human cell-based high-throughput phenotypic screening, clinically relevant disease models, and AI-enabled discovery tools to identify and validate new molecular entities, with a particular emphasis on mitophagy biology. Its disclosed disease focus included Parkinson's disease, amyotrophic lateral sclerosis, and Alzheimer's disease. Rosetta also participated in a University of Toronto and Cyclica collaboration supported by Genome Canada for Parkinson's drug discovery. Corporate records indicate the company was dissolved in August 2022 and multiple business databases now classify it as closed.